Collegium Pharmaceutical Inc (NASDAQ: COLL) on Monday, soared 3.46% from the previous trading day, before settling in for the closing price of $34.93. Within the past 52 weeks, COLL’s price has moved between $23.23 and $42.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 19.63%. With a float of $30.18 million, this company’s outstanding shares have now reached $31.55 million.
In an organization with 357 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 57.69%, operating margin of 21.39%, and the pretax margin is 9.8%.
Collegium Pharmaceutical Inc (COLL) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Collegium Pharmaceutical Inc is 4.21%, while institutional ownership is 118.50%. The most recent insider transaction that took place on Jul 09 ’25, was worth 332,269. Before that another transaction happened on Jul 08 ’25, when Company’s Former Director proposed sale 790 for $31.38, making the entire transaction worth $24,792.
Collegium Pharmaceutical Inc (COLL) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 1.61 earnings per share (EPS) for the period topping the consensus outlook (set at 1.59) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.63% per share during the next fiscal year.
Collegium Pharmaceutical Inc (NASDAQ: COLL) Trading Performance Indicators
Collegium Pharmaceutical Inc (COLL) is currently performing well based on its current performance indicators. A quick ratio of 1.10 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.61. Likewise, its price to free cash flow for the trailing twelve months is 5.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.04, a number that is poised to hit 2.03 in the next quarter and is forecasted to reach 7.85 in one year’s time.
Technical Analysis of Collegium Pharmaceutical Inc (COLL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.6 million. That was better than the volume of 0.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.33%.
During the past 100 days, Collegium Pharmaceutical Inc’s (COLL) raw stochastic average was set at 96.34%, which indicates a significant increase from 93.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.18 in the past 14 days, which was higher than the 0.97 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.87, while its 200-day Moving Average is $30.30. However, in the short run, Collegium Pharmaceutical Inc’s stock first resistance to watch stands at $36.87. Second resistance stands at $37.60. The third major resistance level sits at $38.57. If the price goes on to break the first support level at $35.17, it is likely to go to the next support level at $34.20. Assuming the price breaks the second support level, the third support level stands at $33.47.
Collegium Pharmaceutical Inc (NASDAQ: COLL) Key Stats
Market capitalization of the company is 1.14 billion based on 32,132K outstanding shares. Right now, sales total 631,450 K and income totals 69,190 K. The company made 177,760 K in profit during its latest quarter, and 2,420 K in sales during its previous quarter.
